Last updated on June 2018

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic Lymphocytic Leukemia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

  1. Documented diagnosis of CLL/SLL according to IWCLL guidelines.

For Screening phase:

  • No pretreatment of CLL/SLL
  • Ability to mount an immune response: Positive immunresponse to EBV/CMV peptide mix (analyzed in 12 day recall IFN ELISPOT).

For Vaccination phase:

Achievement of response (at least PR according to IWCLL guidelines) after first-line therapy according to treating physicians choice.

2. HLA typing positive for HLA alleles of peptides included in the warehouse with proven immunogenicity: HLA-A01, A02, A03, A24, B07, B08.

3. Ability to understand and voluntarily sign an informed consent form.

4. Age 18 years at the time of signing the informed consent form.

5. Ability to adhere to the study visit schedule and other protocol requirements.

6. Eastern Cooperative Oncology Group (ECOG) performance status score of 2.

7. Negative serological Hepatitis B and C test or negative PCR in case of positive serological test without evidence of an active infection, negative HIV test within 6 weeks prior to randomization.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.